CTOs on the Move

Affinium Pharmaceuticals

www.afnm.com

 
Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.afnm.com
  • 100 University Ave
    Toronto, ON CAN M5J 1V6
  • Phone: 416.645.6600

Executives

Name Title Contact Details

Similar Companies

Auxilium

Auxilium is a fully integrated specialty biopharmaceutical company focused on developing and marketing products to predominantly specialist audiences. Auxilium means “assistance” in Latin, and that’s a fitting description for all of our biopharmaceutical development and commercialization efforts. Although we are living in an era of rapid advances in medical technology, many of society’s medical concerns remain unaddressed. Auxilium works to address some of these unmet needs. By doing so, we work in important areas of the pharmaceutical industry that require forward thinking and novel solutions that promote better health and living. Through advancement and expansion, Auxilium is dedicated to providing innovative solutions for underserved diseases that improve health and quality of life.

Sorenson Forensics

Sorenson Forensics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ferndale Laboratories

Ferndale Laboratories, Inc. is a Ferndale, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tishcon Corp

Tishcon Corp is a Salisbury, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ohr Pharmaceutical

Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company`s lead product, Squalamine (OHR-102), is currently being studied as an eye drop formulation in several company sponsored and investigator sponsored Phase II clinical trials for various back-of-the-eye diseases, including the wet form of age-related macular degeneration, retinal vein occlusion, diabetic macular edema, and proliferative diabetic retinopathy. In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.